Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Abstract Text:

E P Mauser-Bunschoten,D Posthouwer,K Fischer,H M van den Berg,

In 1995, AAFACT, a new monoclonal purified factor VIII concentrate (FVIII), derived from human plasma, was introduced in the Netherlands. The monoclonal purification based production process includes a viral inactivation step by solvent/detergent treatment. Products manufactured according to this procedure, for example Hemofil M are used worldwide. The aim of the present study was to assess inhibitor development in a large cohort of previously treated patients (PTPs) who were followed up for 10 years. In addition, efficacy, HIV and hepatitis C virus (HCV) transmission, and allergic reactions were monitored. All 165 patients with severe haemophilia A (FVIII<1%) known at the van Creveldkliniek who ever used AAFACT during the period from October 1995 to September 2005 were included. Two of them were previously untreated patients (PUPs) and two others had <50 exposure days. Data on FVIII consumption, number of exposures, bleedings and hospitalization days were collected from start of AAFACT until last clinical and laboratory evaluation while on this product. At the end of follow-up, 91 patients were still using this plasma-derived FVIII. Median age at start of follow-up was 26 years (range 1-52). None of the patients reported lack of efficacy. Median FVIII consumption per patient during follow-up was 2058 IU kg(-1) bodyweight per year, and median number of exposures was 148 per year. During 1029 patient-years of follow-up, one inhibitor was diagnosed in a previously treated patient PTP. This patient developed high titre inhibitor following surgery for which he, during 1 week, had been treated with continuous infusion with recombinant FVIII. No inhibitor occurred during 68 cases of surgery using continuous infusion with AAFACT. No viral transmissions or other adverse events occurred during 10 years of follow-up; AAFACT appeared to be an effective and safe FVIII product.

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Publishing Authors By Initials

EP Mauser-Bunschoten,D Posthouwer,K Fischer,HM van den Berg,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Haemophilia : the official journal of the World Fe

VOLUME: 13

Page Numbers: 697-700

Journal Abbreviation:

ISSN: 1351-8216

DAY: 18

MONTH: 09

YEAR: 2007

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9442916

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.

AFFILIATION: Van Creveldkliniek, Division of Internal Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands. E.Mauserbunschoten@umcutrecht.nl

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Haemophilia

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up Related Publications

• Bone morphogenetic protein 2 stimulates articular cartilage proteoglycan synthesis in vivo but does not counteract interleukin-1alpha effects on proteoglycan synthesis and content.
• Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options.
• Collision judgment of objects approaching the head.
• Communication between the corpus cavernosum penis and the corpus spongiosum penis in a bull diagnosed by modified contrast cavernosography: A case report.
• Crucial role of synovial lining macrophages in the promotion of transforming growth factor beta-mediated osteophyte formation.
• Delayed intrauterine repair of an experimental spina bifida with a collagen biomatrix.
• Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation.
• Energy conversion in microsystems: is there a role for micro/nanofluidics?
• Flash suppression and flash facilitation in binocular rivalry.
• Gene transfer and protein dynamics in stem cells using single cell electroporation in a microfluidic device.
• HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma.
• High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics.
• ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study.
• Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis.
• Lifetime occupation, education, smoking, and risk of ALS.
• Media exposure, mood, and body image dissatisfaction: an experimental test of person versus product priming.
• Multiphase flow in microfluidic systems --control and applications of droplets and interfaces.
• Oral or IV Prednisolone in the Treatment of COPD Exacerbations: A Randomized, Controlled, Double-blind Study.
• Phenotypic differences in murine chondrocyte cell lines derived from mature articular cartilage.
• Pivotal role of ChIFNgamma in the pathogenesis and immunosuppression of infectious bursal disease.
• RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia.
• Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
• Redox cycling with facing interdigitated array electrodes as a method for selective detection of redox species.
• Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis.
• Role of nitric oxide in the inhibition of BMP-2-mediated stimulation of proteoglycan synthesis in articular cartilage.
• Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
• Shared risk and protective factors for overweight and disordered eating in adolescents.
• Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-beta into murine knee joints.
• Structural insight into OprD substrate specificity.
• Vascular events after liver transplantation: a long-term follow-up study.